Trial
NCT03235869
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
Early Phase IWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
University of Michigan Rogel Cancer Center
Collaborators
—
Condition
Cutaneous T Cell Lymphoma
Intervention
Durvalumab
Why stopped
The company pulled durvalumab from heme malignancies
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-03-15